2022-502888-38-00CompletedPhase 2
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
J4E-MC-IMMB: A Master Protocol for Randomized, Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis; J4E-MC-FR01: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis
Source: EU CTIS (euclinicaltrials.eu) · Last updated 1 Jul 2026
Brief summary (registry, in English)
To compare the efficacy of LY3454738 versus placebo as measured by EASI-75 in the treatment of biologic-and-small-molecule—naïve participants with moderate-to-severe Atopic Dermatitis
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 94 (actual)
- First submitted
- 18 Apr 2023
- Start date
- 25 Sept 2023
- Lead sponsor
- Eli Lilly & Co.
- Diseases
- Atopic dermatitis (eczema)
- EU CT number
- 2022-502888-38-00
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 94
- 16 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have any prior skin infections requiring treatment with topical corticosteroids.
Other illness
- Have history of psoriasis
- Have other infections such as Hepatitis B or C
- Known allergy to study drug or any components to formulation or history of drug hypersensitivity reactions.
Who the study is looking for
- Have active atopic dermatitis for over a year and include the following:
- EASI score ≥ 12 at first dosing visit
- vIGA-AD score ≥3 at first dosing visit
- Have ≥10% of BSA involvement (per EASI BSA) at first dosing visit
- Have little improvement with topical medicines.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (16)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Debrecen | Debrecen | Hungary | Completed |
| Somogy Megyei Kaposi Mór Oktató Kórház | Kaposvár | Hungary | Completed |
| Allergo-Derm Bakos Kft | Szolnok | Hungary | Completed |
| University Teaching Hospital Markusovszky | Szombathely | Hungary | Completed |
| Medmare Bt. | Veszprém | Hungary | Completed |
| Azienda Ospedaliero-Universitaria delle Marche | Ancona | Italy | Withdrawn |
| Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Brescia | Italy | Withdrawn |
| Humanitas Research Hospital | Rozzano | Italy | Withdrawn |
| Azienda Ospedaliera Universitaria Senese | Siena | Italy | Withdrawn |
| Specderm Poznanska sp.j. | Bialystok | Poland | Completed |
| Diamond Clinic Sp. z o.o. | Cracow | Poland | Completed |
| Centrum Badan Klinicznych PI-House sp. z o.o. | Gdansk | Poland | Completed |
| Dermoklinika-Medyczne Centrum s.c. M.Kierstan J.Narbutt A.Lesiak | Lodz | Poland | Completed |
| DERMED Centrum Medyczne Sp. z o.o. | Lodz | Poland | Completed |
| Evimed Sp. z o.o. | Warsaw | Poland | Completed |
| Medicover Integrated Clinical Services Sp. z o.o. | Warsaw | Poland | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.